FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983158288> ?p ?o ?g. }

• W2983158288 abstract "Abstract PURPOSE/OBJECTIVES We set out to predict response and progression risk in recurrent high-grade glioma patients treated with hypofractionated stereotactic radiation plus pembrolizumab and bevacizumab (NCT02313272). At present RANO criteria define progression as 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement (either at baseline or best response) or significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids. To this extent, a predictive model is needed to adaptively learn and forecast individual response to therapy. We evaluate if early tumor volume evolution can train a mathematical model to predict subsequent response to therapy. MATERIALS/METHODS We develop a mathematical model that describes patient-uniform tumor growth rate and initial pembrolizumab and bevacizumab responses, and patient-specific treatment response dynamics. A total of 154 radiology scans were delineated to derive longitudinal tumor volumes of 26 patients. In a leave-one-out study, patient-uniform model parameters are derived and then applied to the left-out patient to adaptively learn treatment response dynamics to forecast tumor volume evolution and progression risk. Model prediction performance is evaluated based on classification accuracy, including sensitivity and specificity. RESULTS Patient-uniform glioma growth rate and initial treatment response rates are estimated to achieve acceptable fits to the longitudinal data of all untrained patients with R2 = 0.81 [0.75, 0.89]. Response dynamics are predicted with high accuracy (0.78 [0.76, 0.79]), with positive and negative predictive values of 0.90 [0.86, 0.92] and 0.81 [0.78, 0.86], and sensitivity and specificity of 0.71 [0.69, 0.73] and 0.88 [0.83, 0.91] respectively. CONCLUSIONS Two patient-specific parameters in a mathematical model can be adaptively learned from early tumor volume evolution to predict subsequent response to therapy and progression risk for individual patients. Future validation is required in an independent dataset and prospective evaluation in another clinical trial." @default.
• W2983158288 created "2019-11-22" @default.
• W2983158288 creator A5001880989 @default.
• W2983158288 creator A5014796235 @default.
• W2983158288 creator A5016146706 @default.
• W2983158288 creator A5021309275 @default.
• W2983158288 creator A5025331599 @default.
• W2983158288 creator A5030248894 @default.
• W2983158288 creator A5048181566 @default.
• W2983158288 creator A5060435181 @default.
• W2983158288 creator A5064973591 @default.
• W2983158288 date "2019-11-01" @default.
• W2983158288 modified "2023-09-23" @default.
• W2983158288 title "COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL" @default.
• W2983158288 doi "https://doi.org/10.1093/neuonc/noz175.256" @default.
• W2983158288 hasPublicationYear "2019" @default.
• W2983158288 type Work @default.
• W2983158288 sameAs 2983158288 @default.
• W2983158288 citedByCount "0" @default.
• W2983158288 crossrefType "journal-article" @default.
• W2983158288 hasAuthorship W2983158288A5001880989 @default.
• W2983158288 hasAuthorship W2983158288A5014796235 @default.
• W2983158288 hasAuthorship W2983158288A5016146706 @default.
• W2983158288 hasAuthorship W2983158288A5021309275 @default.
• W2983158288 hasAuthorship W2983158288A5025331599 @default.
• W2983158288 hasAuthorship W2983158288A5030248894 @default.
• W2983158288 hasAuthorship W2983158288A5048181566 @default.
• W2983158288 hasAuthorship W2983158288A5060435181 @default.
• W2983158288 hasAuthorship W2983158288A5064973591 @default.
• W2983158288 hasBestOaLocation W29831582881 @default.
• W2983158288 hasConcept C121608353 @default.
• W2983158288 hasConcept C126322002 @default.
• W2983158288 hasConcept C143998085 @default.
• W2983158288 hasConcept C2776694085 @default.
• W2983158288 hasConcept C2777701055 @default.
• W2983158288 hasConcept C2777802072 @default.
• W2983158288 hasConcept C2778227246 @default.
• W2983158288 hasConcept C2780057760 @default.
• W2983158288 hasConcept C502942594 @default.
• W2983158288 hasConcept C509974204 @default.
• W2983158288 hasConcept C71924100 @default.
• W2983158288 hasConceptScore W2983158288C121608353 @default.
• W2983158288 hasConceptScore W2983158288C126322002 @default.
• W2983158288 hasConceptScore W2983158288C143998085 @default.
• W2983158288 hasConceptScore W2983158288C2776694085 @default.
• W2983158288 hasConceptScore W2983158288C2777701055 @default.
• W2983158288 hasConceptScore W2983158288C2777802072 @default.
• W2983158288 hasConceptScore W2983158288C2778227246 @default.
• W2983158288 hasConceptScore W2983158288C2780057760 @default.
• W2983158288 hasConceptScore W2983158288C502942594 @default.
• W2983158288 hasConceptScore W2983158288C509974204 @default.
• W2983158288 hasConceptScore W2983158288C71924100 @default.
• W2983158288 hasLocation W29831582881 @default.
• W2983158288 hasLocation W29831582882 @default.
• W2983158288 hasOpenAccess W2983158288 @default.
• W2983158288 hasPrimaryLocation W29831582881 @default.
• W2983158288 isParatext "false" @default.
• W2983158288 isRetracted "false" @default.
• W2983158288 magId "2983158288" @default.
• W2983158288 workType "article" @default.